Moffitt and Fulgent Pharma partner on personalised cancer therapies

15 May 2024
·
Deals
www.pharmaceutical-technology.com
Phase 1AcquisitionDrug ApprovalLicense out/inPhase 2
Moffitt and Fulgent Pharma partner on personalised cancer therapies
Preview
Source: Pharmaceutical Technology
Fulgent’s soluble form of paclitaxel has demonstrated significant tumour reduction in various cancer types in Phase I studies. Credit: Lightspring / Shutterstock.com.
Moffitt Cancer CenterCancer Center and Fulgent Pharma have announced a strategic partnership to enhance the development of personalised cancer therapies.
The companies will join forces to progress therapeutics through pre-clinical co-development and clinical development.
The collaboration unites the clinical expertise of Moffitt with Fulgent’s nanotherapeutics and genomics platforms to expedite the creation of targeted cancer treatments.
The agreement grants Fulgent priority access to Moffitt’s clinical capabilities and resources, which will accelerate the progression of Fulgent’s clinical pipeline.
This includes prioritised activation of clinical trials, improved patient screening and efficient data sharing to swiftly deliver investigational therapies to patients.
See Also:Pint Pharma announces Orladeyo approval in Mexico for HAE prevention
Moffitt and Fulgent Pharma partner on personalised cancer therapies
Preview
Source: Pharmaceutical Technology
Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
Moffitt and Fulgent Pharma partner on personalised cancer therapies
Preview
Source: Pharmaceutical Technology
Fulgent Pharma, with expertise in nanoencapsulation technology, developed a soluble form of the chemotherapy drug paclitaxel, named FID-007.
Early Phase I clinical studies have shown significant tumour reduction in breast, head and neck, lung, bile duct, and pancreatic cancers using soluble intravenous FID-007 injection.
The partnership will also focus on co-developing new tailored cancer treatments.
Moffitt will utilise its extensive scientific and immunology knowledge, tissue sample access and nonclinical research resources. Fulgent will provide its nano-particle-based drug development platform and comprehensive genetic and genomic testing capabilities.
Moffitt president and CEO Patrick Hwu stated: “This partnership aligns with Moffitt’s mission to contribute to the prevention and cure of cancer. We are looking forward to working with Fulgent to accelerate the translation of scientific discoveries into lifesaving treatments for our patients.”
In November 2022, Fulgent Pharma was acquired by Fulgent Genetics for $100m.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.